Teva Pharmaceutical Industries (TEVA) Long-Term Investments (2009 - 2011)

Teva Pharmaceutical Industries has disclosed Long-Term Investments across 3 years of filings, most recently posting $991.0 million for Q4 2011.

• Quarterly Long-Term Investments rose 56.8% year-over-year to $991.0 million in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $991.0 million (up 56.8% YoY) and the FY2011 annual result came in at $991.0 million, up 56.8% from the prior year.
• Long-Term Investments climbed to $991.0 million in Q4 2011, from $632.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $991.0 million in Q4 2011 and troughed at $534.0 million in Q4 2009.
• A 3-year average of $719.0 million and a median of $632.0 million in 2010 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2010 — Long-Term Investments advanced 18.35% — and 2011, when it soared 56.8%.
• Tracing TEVA's Long-Term Investments over 3 years: stood at $534.0 million in 2009, then gained by 18.35% to $632.0 million in 2010, then surged by 56.8% to $991.0 million in 2011.
• Business Quant data shows TEVA's Long-Term Investments at $991.0 million in Q4 2011, $632.0 million in Q4 2010, and $534.0 million in Q4 2009.